Blar i forfatter "Engesæter, Birgit Øvstebø"

Viser treff 1-3 av 3

    • Dacarbazine and the Agonistic TRAIL Receptor-2 Antibody Lexatumumab Induce Synergistic Anticancer Effects in Melanoma 

      Engesæter, Birgit Øvstebø; Engebråten, Olav; Flørenes, Vivi Ann; Mælandsmo, Gunhild (Journal article; Tidsskriftartikkel; Peer reviewed, 2012)
      Mapatumumab and lexatumumab (targeting death receptor 4 (DR4) and 5 (DR5), respectively) are agonistic TRAIL receptor antibodies that induce apoptosis in a wide range of cancer cells. The potency of mapatumumab and lexatumumab was assessed in mono therapy protocols, and the ability to sensitize for dacarbazine (DTIC) treatment was explored in ten different melanoma cell lines. Our data indicated ...

    • Fibroblast-induced switching to the mesenchymal-like phenotype and PI3K/mTOR signaling protects melanoma cells from BRAF inhibitors 

      Vasiliauskaite, Kotryna; Fleten, Karianne Giller; Barkovskaya, Anna; Nygaard, Vigdis; Haugen, Mads Haugland; Engesæter, Birgit Øvstebø; Mælandsmo, Gunhild; Prasmickaite, Lina (Journal article; Tidsskriftartikkel; Peer reviewed, 2016)
      The knowledge on how tumor-associated stroma influences efficacy of anti-cancer therapy just started to emerge. Here we show that lung fibroblasts reduce melanoma sensitivity to the BRAF inhibitor (BRAFi) vemurafenib only if the two cell types are in close proximity. In the presence of fibroblasts, the adjacent melanoma cells acquire de-differentiated mesenchymal-like phenotype. Upon treatment with ...

    • Psychological effect of cervical cancer screening when changing primary screening method from cytology to high-risk human papilloma virus testing 

      Andreassen, Trude; Hansen, Bo Terning; Engesæter, Birgit Øvstebø; Hashim, Dana; Støer, Nathalie Charlotte; Trope, Ameli; Moen, Kåre; Ursin, Giske; Weiderpass, Elisabete (Journal article; Tidsskriftartikkel; Peer reviewed, 2018-12-14)
      From 2015, Norway has implemented high‐risk human papilloma virus (hrHPV) testing in primary screening for cervical cancer. Women aged 34–69 years, living in four counties, have been pseudo‐randomly assigned (1:1 randomization) to either hrHPV testing every 5 years (followed by cytology if hrHPV is positive), or cytology testing every 3 years (followed by hrHPV testing if low‐grade cytology is ...